Accendra Health Names Kenneth Gardner-Smith as President and Chief Executive Officer to Lead the Company's Next Chapter of Growth

RICHMOND, Va.--(BUSINESS WIRE)--Accendra Health, Inc. (NYSE: ACH) (the “Company”) today named Kenneth Gardner-Smith as the Company's next President and Chief Executive Officer. Gardner-Smith, who has served on the Company's Board of Directors since March 2022, is expected to assume the role early in the fourth quarter 2026. He will succeed Edward A. Pesicka, who announced his intent to retire in August. Gardner-Smith brings deep experience running large-scale patient care operations and guiding.

Business Wire • Sep 17, 2026

Accendra Health Updates on Capital Allocation and CEO Succession Timing Plans

RICHMOND, Va.--(BUSINESS WIRE)--Accendra Health (the “Company”) is providing an update on its capital allocation plans and the timeline for the replacement of its chief executive officer. Given recent market conditions, the Company has determined that it is in the best interest of stakeholders not to put in place an at-the-market issuance program. The program was intended to allow the Company to opportunistically issue modest amounts of equity over time, with the proceeds to be used to reduce o.

Business Wire • Aug 17, 2026

Accendra Health, Inc. (ACH) Q2 2026 Earnings Call Transcript

Accendra Health, Inc. (ACH) Q2 2026 Earnings Call Transcript

Seeking Alpha • Aug 10, 2026

Accendra Health Reports Second Quarter 2026 Financial Results

RICHMOND, Va.--(BUSINESS WIRE)--Accendra Health, Inc. (NYSE: ACH) (the Company) today reported financial results for the second quarter ended June 30, 2026. Unless otherwise noted, the results herein reflect the Company's continuing operations, which represent what was previously the Patient Direct segment and certain functional operations. “Throughout the second quarter, we moved farther along toward the complete separation from Owens & Minor while also putting a large commercial payor exi.

Business Wire • Aug 10, 2026

Accendra Health's Ed Pesicka Announces Intent to Retire; Board of Directors Has Begun Successor Search

RICHMOND, Va.--(BUSINESS WIRE)--Accendra Health, Inc. (NYSE: ACH) (the Company) today announced that President and Chief Executive Officer Edward A. Pesicka has informed the Board of Directors of his plan to retire by the end of 2026, after more than seven years with the Company. Mr. Pesicka will also retire from the Company's Board of Directors before the end of the year. The Board of Directors maintains a long-standing, robust succession planning process established to address officer success.

Business Wire • Aug 10, 2026

Accendra Health Announces Adoption of Tax Asset Preservation Plan To Protect Long Term Shareholder Value

RICHMOND, Va.--(BUSINESS WIRE)--Accendra Health, Inc. (NYSE: ACH) (the Company) announced today that its Board of Directors adopted a Section 382 Rights Agreement (the “Tax Asset Preservation Plan”) designed to protect long-term shareholder value by facilitating the Company's ability to preserve its net operating loss carryforwards (“NOLs”) and certain other tax attributes. A company generally experiences an ownership change if the percentage of the value of its stock owned by certain “5-percen.

Business Wire • Aug 10, 2026

Accendra Health Q2 Preview: Low Expectations Create Opportunity

Accendra Health remains a speculative buy despite recent share declines and sector-driven volatility. ACH's limited exposure to capitated contracts and prudent exit from risky agreements mitigate margin risk seen in peers like AHCO. Balance sheet restructuring has reduced gross borrowings by at least $350 million, extending maturities and enabling future deleveraging.

Seeking Alpha • Aug 5, 2026

Accendra Health Announces Second Quarter 2026 Earnings Release Date and Conference Call

RICHMOND, Va.--(BUSINESS WIRE)--Accendra Health, Inc. (NYSE: ACH) (the “Company”) plans to release financial results for the second quarter of 2026 on Monday, August 10, 2026, before trading begins on the New York Stock Exchange. The Company will host a conference call for investors and analysts at 8:00 a.m. EDT on the same day. Participants may access the call via the toll-free dial-in number at 1-888-300-2035, or the toll dial-in number at 1-646-517-7437. The conference ID access code is 1058.

Business Wire • Jul 27, 2026

Is the Options Market Predicting a Spike in Accendra Health Stock?

Investors need to pay close attention to ACH stock based on the movements in the options market lately.

Zacks Investment Research • Jul 2, 2026

Accendra Health Announces Expiration and Final Results of Offers and Consent Solicitations

RICHMOND, Va.--(BUSINESS WIRE)--Accendra Health, Inc. (NYSE: ACH) (the “Company”) today announced the expiration and final results of the previously announced offers to exchange (the “Exchange Offers”) any and all of the Company's outstanding 4.500% Senior Notes due 2029 (the “2029 Notes”) and 6.625% Senior Notes due 2030 (the “2030 Notes” and, together with the 2029 Notes, the “Existing Notes”). As of 5:00 P.M., New York City time, on June 23, 2026 (the “Expiration Time”), the Company received.

Business Wire • Jun 24, 2026